Market Signal Briefing

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price. Do they really matter, though?

Let's take a look at what these Wall Street heavyweights have to say about Tutor Perini (TPC - Free Report) before we discuss the reliability of brokerage recommendations and how to use them to your advantage.

Tutor Perini currently has an average brokerage recommendation (ABR) of 1.33, on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell, etc.) made by six brokerage firms. An ABR of 1.33 approximates between Strong Buy and Buy.

Of the six recommendations that derive the current ABR, five are Strong Buy, representing 83.3% of all recommendations.

Brokerage Recommendation Trends for TPC

Check price target & stock forecast for Tutor Perini here>>>

The ABR suggests buying Tutor Perini, but making an investment decision solely on the basis of this information might not be a good idea. According to several studies, brokerage recommendations have little to no success guiding investors to choose stocks with the most potential for price appreciation.

Do you wonder why? As a result of the vested interest of brokerage firms in a stock they cover, their analysts tend to rate it with a strong positive bias. According to our research, brokerage firms assign five "Strong Buy" recommendations for every "Strong Sell" recommendation.

In other words, their interests aren't always aligned with retail investors, rarely indicating where the price of a stock could actually be heading. Therefore, the best use of this information could be validating your own research or an indicator that has proven to be highly successful in predicting a stock's price movement.

Zacks Rank, our proprietary stock rating tool with an impressive externally audited track record, categorizes stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), and is an effective indicator of a stock's price performance in the near future. Therefore, using the ABR to validate the Zacks Rank could be an efficient way of making a profitable investment decision.

ABR Should Not Be Confused With Zacks RankIn spite of the fact that Zacks Rank and ABR both appear on a scale from 1 to 5, they are two completely different measures.

Broker recommendations are the sole basis for calculating the ABR, which is typically displayed in decimals (such as 1.28). The Zacks Rank, on the other hand, is a quantitative model designed to harness the power of earnings estimate revisions. It is displayed in whole numbers -- 1 to 5.

Analysts employed by brokerage firms have been and continue to be overly optimistic with their recommendations. Since the ratings issued by these analysts are more favorable than their research would support because of the vested interest of their employers, they mislead investors far more often than they guide.

In contrast, the Zacks Rank is driven by earnings estimate revisions. And near-term stock price movements are strongly correlated with trends in earnings estimate revisions, according to empirical research.

Furthermore, the different grades of the Zacks Rank are applied proportionately across all stocks for which brokerage analysts provide earnings estimates for the current year. In other words, at all times, this tool maintains a balance among the five ranks it assigns.

There is also a key difference between the ABR and Zacks Rank when it comes to freshness. When you look at the ABR, it may not be up-to-date. Nonetheless, since brokerage analysts constantly revise their earnings estimates to reflect changing business trends, and their actions get reflected in the Zacks Rank quickly enough, it is always timely in predicting future stock prices.

Is TPC Worth Investing In?Looking at the earnings estimate revisions for Tutor Perini, the Zacks Consensus Estimate for the current year has remained unchanged over the past month at $4.72.

Analysts' steady views regarding the company's earnings prospects, as indicated by an unchanged consensus estimate, could be a legitimate reason for the stock to perform in line with the broader market in the near term.

The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #3 (Hold) for Tutor Perini. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>

It may therefore be prudent to be a little cautious with the Buy-equivalent ABR for Tutor Perini.

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?

Before we discuss the reliability of brokerage recommendations and how to use them to your advantage, let's see what these Wall Street heavyweights think about JPMorgan Chase & Co. (JPM - Free Report) .

JPMorgan Chase & Co. currently has an average brokerage recommendation (ABR) of 2.00, on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell, etc.) made by 29 brokerage firms. An ABR of 2.00 indicates Buy.

Of the 29 recommendations that derive the current ABR, 13 are Strong Buy and three are Buy. Strong Buy and Buy respectively account for 44.8% and 10.3% of all recommendations.

Brokerage Recommendation Trends for JPM

Check price target & stock forecast for JPMorgan Chase & Co. here>>>

While the ABR calls for buying JPMorgan Chase & Co., it may not be wise to make an investment decision solely based on this information. Several studies have shown limited to no success of brokerage recommendations in guiding investors to pick stocks with the best price increase potential.

Are you wondering why? The vested interest of brokerage firms in a stock they cover often results in a strong positive bias of their analysts in rating it. Our research shows that for every "Strong Sell" recommendation, brokerage firms assign five "Strong Buy" recommendations.

In other words, their interests aren't always aligned with retail investors, rarely indicating where the price of a stock could actually be heading. Therefore, the best use of this information could be validating your own research or an indicator that has proven to be highly successful in predicting a stock's price movement.

Zacks Rank, our proprietary stock rating tool with an impressive externally audited track record, categorizes stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), and is an effective indicator of a stock's price performance in the near future. Therefore, using the ABR to validate the Zacks Rank could be an efficient way of making a profitable investment decision.

ABR Should Not Be Confused With Zacks RankAlthough both Zacks Rank and ABR are displayed in a range of 1--5, they are different measures altogether.

The ABR is calculated solely based on brokerage recommendations and is typically displayed with decimals (example: 1.28). In contrast, the Zacks Rank is a quantitative model allowing investors to harness the power of earnings estimate revisions. It is displayed in whole numbers -- 1 to 5.

It has been and continues to be the case that analysts employed by brokerage firms are overly optimistic with their recommendations. Because of their employers' vested interests, these analysts issue more favorable ratings than their research would support, misguiding investors far more often than helping them.

In contrast, the Zacks Rank is driven by earnings estimate revisions. And near-term stock price movements are strongly correlated with trends in earnings estimate revisions, according to empirical research.

In addition, the different Zacks Rank grades are applied proportionately to all stocks for which brokerage analysts provide current-year earnings estimates. In other words, this tool always maintains a balance among its five ranks.

There is also a key difference between the ABR and Zacks Rank when it comes to freshness. When you look at the ABR, it may not be up-to-date. Nonetheless, since brokerage analysts constantly revise their earnings estimates to reflect changing business trends, and their actions get reflected in the Zacks Rank quickly enough, it is always timely in predicting future stock prices.

Should You Invest in JPM?In terms of earnings estimate revisions for JPMorgan Chase & Co., the Zacks Consensus Estimate for the current year has increased 1.7% over the past month to $21.73.

Analysts' growing optimism over the company's earnings prospects, as indicated by strong agreement among them in revising EPS estimates higher, could be a legitimate reason for the stock to soar in the near term.

The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #1 (Strong Buy) for JPMorgan Chase & Co. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>

Therefore, the Buy-equivalent ABR for JPMorgan Chase & Co may serve as a useful guide for investors.

Key Takeaways Newmont shares jumped 154.5% in a year, driven by record gold prices and strong operational performance.NEM is expanding production with projects like Cadia Panel Caves and Tanami Expansion 2.NEM generated $3.6B from asset sales and returned $3.4B to shareholders via dividends and buybacks in 2025. Newmont Corporation's (NEM - Free Report) shares have shot up 154.5% in the past year, thanks to an upswing in gold prices to record highs. The company’s strong earnings performance, driven by its operational efficiency and the strength of its Tier 1 portfolio, also contributed to the rally.

 NEM stock has outperformed the Zacks Mining – Gold industry’s 131.2% rally and the S&P 500’s rise of 26.1%. Among its gold mining peers, Barrick Mining Corporation (B - Free Report) , Agnico Eagle Mines Limited (AEM - Free Report) and Kinross Gold Corporation (KGC - Free Report) have rallied 142.6%, 117% and 185.6%, respectively, over the same period.

NEM’s One-year Price Performance     Image Source: Zacks Investment Research

The NEM stock has been trading above its 200-day simple moving average (SMA) since April 9, 2025, suggesting a long-term uptrend. It slipped below its 50-day SMA yesterday amid a pullback in gold prices on inflation worries. Nevertheless, the 50-day SMA is reading higher than the 200-day SMA, following a golden crossover on April 16, 2025, indicating a bullish trend.      

NEM Stock Trades Below 50-Day SMA Image Source: Zacks Investment Research

Is the time right to buy NEM’s shares for potential upside? Let’s take a look at the stock’s fundamentals.

Key Projects & Asset Streamlining to Aid NEM’s GrowthNewmont continues to invest in growth projects in a calculated manner. The company is pursuing several projects, including the Cadia Panel Caves and Tanami Expansion 2 in Australia. These projects should expand Newmont’s production capacity and extend mine life, driving revenues and profits.

In October 2025, NEM achieved a significant milestone at Ahafo North. It achieved commercial production at the project, which followed the first gold pour in September 2025. Ahafo North is expected to produce between 275,000 and 325,000 ounces of gold annually over an estimated mine life of 13 years. Output is expected to be 315,000 ounces this year, with a ramp-up to full capacity.

Newmont has also divested non-core businesses as it shifts its strategic focus to Tier 1 assets.  NEM completed its non-core divestiture program in April 2025, with the sale of its Akyem operation in Ghana and its Porcupine operation in Canada. NEM has executed agreements to sell its shares in Greatland Resources Limited and Discovery Silver Corp, for total cash proceeds of around $470 million after taxes and commissions.

The company generated $3.6 billion from its portfolio optimization actions in 2025. These funds will support Newmont’s capital allocation strategy, which focuses on reinforcing its balance sheet and delivering returns to its shareholders.

Solid Financial Health Supports NEM’s Capital AllocationNewmont has a strong liquidity position and generates substantial cash flows, which allow it to fund its growth projects, meet short-term debt obligations and drive shareholder value. At the end of 2025, Newmont had robust liquidity of roughly $11.6 billion, including cash and cash equivalents of around $7.6 billion. Its free cash flow nearly doubled year over year to a record $2.8 billion in the fourth quarter and surged two-and-a-half-fold year over year to a record $7.3 billion, led by an increase in net cash from operating activities. Net cash from operating activities shot up 44% from the prior-year quarter to $3.6 billion, and surged 62% to $10.3 billion in 2025.

NEM has distributed $3.4 billion to its shareholders through dividends and share repurchases in 2025. It also remains committed to deleveraging, reducing debt by roughly $3.4 billion in 2025, resulting in a strong net cash position of $2.1 billion. NEM announced an increased dividend of 26 cents per share for the fourth quarter of 2025. Newmont has executed $3.6 billion from $6 billion of buyback authorization as of Feb. 19, 2026.

Newmont stands to benefit from the strength in gold prices, which should drive its profitability and cash flow generation. Gold prices saw a record-setting rally last year, mainly attributable to aggressive trade policies, including sweeping new import tariffs announced by President Donald Trump, which have intensified global trade tensions and heightened investor anxiety. Also, central banks worldwide have been accumulating gold reserves, led by risks arising from Trump’s policies.

The yellow metal entered 2026 with a stronger momentum. Heightened geopolitical strains, triggered by U.S.-Iran tensions, a weaker U.S. dollar and concerns over the independence of the Federal Reserve fueled the spike in bullion to record levels, with prices soaring to a fresh high of nearly $5,600 per ounce in late January.

This was followed by a brief pullback to below $4,900 per ounce due to aggressive profit-booking and a rebound in the U.S. dollar after hitting a four-year low. Bargain hunting following the massive selloff again pushed up prices to above $5,000 per ounce.

Gold gained strength earlier this month, surging past $5,400 per ounce on March 2 amid strong safe-haven demand after the United States and Israel began joint strikes on Iran, leading to a major escalation. Gold prices have again pulled back from that level due to a stronger U.S. dollar and reduced expectations of Federal Reserve rate cuts on inflation worries amid a spike in oil prices, currently hovering above $5,100 per ounce.

Increased central bank buying and persistent safe-haven demand driven by the war in the Middle East and concerns over further escalation in the coming days, as well as broader macroeconomic uncertainty, are expected to underpin gold prices.

NEM offers a dividend yield of 0.9% at the current stock price. Its payout ratio is 14% (a ratio below 60% is a good indicator that the dividend will be sustainable). Backed by strong cash flows and sound financial health, the company's dividend is perceived as safe and reliable.

NEM’s Earnings Estimates Moving HigherNewmont’s earnings estimates for 2026 have been going up over the past 60 days. The Zacks Consensus Estimate for 2027 has also been revised higher over the same time frame.

The Zacks Consensus Estimate for 2026 earnings is currently pegged at $8.79, suggesting year-over-year growth of 27.6%. Earnings are expected to grow roughly 17.6% in 2027.

Image Source: Zacks Investment Research

A Look at Newmont Stock’s ValuationNewmont is currently trading at a forward price/earnings of 12.99X, a modest 0.8% discount to the industry’s average of 13.1X. NEM is trading at a premium to Barrick and Kinross Gold and at a discount to Agnico Eagle. Newmont currently has a Value Score of C. Barrick and Kinross Gold have a Value Score of B each, while Agnico Eagle has a Value Score of D.

NEM’s P/E F12M Vs. Industry, B, AEM and KGC Image Source: Zacks Investment Research

Final Thoughts: Buy NEM SharesNewmont is well-placed for growth with the strong performance of its Tier 1 assets and a robust portfolio of projects, which should expand production capacity and extend mine life, thereby driving revenues and profits. The asset streamlining rooted in Newmont’s objective to concentrate capital on high-return, long-life assets also underpins its long-term sustainability. Other positives include rising earnings estimates and a healthy growth trajectory. Favorable bullion prices should also boost NEM’s profitability and drive cash flow generation. With a positive earnings outlook, Newmont looks poised to deliver attractive returns to its investors, making this Zacks Rank #1 (Strong Buy) stock a prudent choice to bet on for those looking to capitalize on the favorable gold market conditions.

 You can see the complete list of today’s Zacks #1 Rank stocks here.

UniFirst (UNF) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Nutrien stock price has staged a strong comeback, reaching its highest point since September 2022. It jumped to $82, up by 100% from its lowest point during the pandemic, with the rally accelerating amid the ongoing Iran war. This surge has pushed its market capitalization to over $38 billion. It may continue rising after forming a cup-and-handle pattern.

Nutrien stock soars as fertilizer prices jump The NTR stock price continued its strong rally this week as the Iran war continued. This war is widely seen as being bullish for Nutrien, a top company in the fertilizer industry.

While crude oil is the main focus on the Strait of Hormuz closure, fertilizer is another major commodity that is being affected as most of it is made in the Middle East.

While fertilizer production is continuing, the main challenge is transporting it through the Strait of Hormuz. This, in turn, will now benefit a company like Nutrien, which makes most of its products in the United States and Canada as fertilizer prices jump.

The most recent results showed that the company's business is doing well, as evidenced by the most recent financial results.

Data showed that its fertilizer volume has continued rising in the past few years, moving from 26.2 million tons in 2023 to over 27.5 million last year.

Its retail adjusted EBITDA has jumped from $1.46 billion to $1.74 billion in the same period. This profitability happened as the company continued cutting its costs, with the capital expenditure falling from $2.6 billion to $2.0 billion last year.

The growing profitability has pushed it to continue boosting its shareholders returns, with the number of outstanding shares falling from 507 million to 482 million, while the dividend per share rising to $2.18.

Nutrien stock has jumped as the company continued its turnaround measures, including disposals worth over $900 million last year. It is hoping to continue the disposal, especially its phosphate business and its operations in Trinidad.

Wall Street analysts are optimistic that Nutrien’s business will continue doing well this year. Data compiled by Yahoo Finance shows that the company will make $5.22 billion this quarter, up by 7.32%. Its annual revenue is expected to move to $26.46 billion this year.

There are also signs that the company is cheap. Data shows that the company has a forward price-to-earnings ratio of 15, lower than the sector median of 17. 

Nutrien share price technical analysis  NTR stock chart | Source: TradingView 

The weekly chart shows that the Nutrien share price has done well in the past few months. It moved from a low of $42 in December 2024 to the current $80.

The stock made a golden cross pattern as the 50-week and 200-week Exponential Moving Averages (EMA) crossed each other.

It is slowly forming a cup-and-handle pattern, a common bullish continuation sign whose upper side is at $102 and the lower side is at $42. 

Top oscillators like the Relative Strength Index (RSI) and the Percentage Price Oscillator (PPO) have continued rising.

Therefore, the most likely scenario is where the stock continues rising, with the next key target being at $102, which is up by 25% above the current level.

NEW YORK, March 12 (Reuters) - Biotechnology ‌company Abivax (ABVX.PA), opens new tab dismissed information published ​by ​French media publication "La ⁠Lettre" saying ​it had ​granted AstraZeneca exclusive access to ​confidential ​information until March 23 ‌to ⁠allow the British pharmaceutical giant ​to ​formalise ⁠a takeover ​offer.

"We deny ​the ⁠information, these are ⁠unfounded ​rumors," ​a spokesperson said.

Keep up with the latest medical breakthroughs and healthcare trends with the Reuters Health Rounds newsletter. Sign up here.

Reporting by ​Sabrina Valle

Our Standards: The Thomson Reuters Trust Principles., opens new tab

NY-based correspondent reporting on some of the largest deals in Healthcare and Industrials. Previously based in Houston, covering global operations of U.S. oil majors. Sabrina has a two-decade career in Business reporting, with a strong background in source-based enterprise and investigations. She previously worked at Bloomberg, Washington Post and has been based in Rio and D.C. covering large corporations, including finance, corruption and geopolitics.

Piedmont Realty Trust (PDM - Free Report) has been on a downward spiral lately with significant selling pressure. After declining 19.9% over the past four weeks, the stock looks well positioned for a trend reversal as it is now in oversold territory and there is strong agreement among Wall Street analysts that the company will report better earnings than they predicted earlier.

We use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is oversold. This is a momentum oscillator that measures the speed and change of price movements.

RSI oscillates between zero and 100. Usually, a stock is considered oversold when its RSI reading falls below 30.

Technically, every stock oscillates between being overbought and oversold irrespective of the quality of their fundamentals. And the beauty of RSI is that it helps you quickly and easily check if a stock's price is reaching a point of reversal.

So, by this measure, if a stock has gotten too far below its fair value just because of unwarranted selling pressure, investors may start looking for entry opportunities in the stock for benefiting from the inevitable rebound.

However, like every investing tool, RSI has its limitations, and should not be used alone for making an investment decision.

Here's Why PDM Could Experience a TurnaroundThe RSI reading of 27.16 for PDM is an indication that the heavy selling could be in the process of exhausting itself, so the stock could bounce back in a quest for reaching the old equilibrium of supply and demand.

The RSI value is not the only factor that indicates a potential turnaround for the stock in the near term. On the fundamental side, there has been strong agreement among the sell-side analysts covering the stock in raising earnings estimates for the current year. Over the last 30 days, the consensus EPS estimate for PDM has increased 1.4%. And an upward trend in earnings estimate revisions usually translates into price appreciation in the near term.

Moreover, PDM currently has a Zacks Rank #2 (Buy), which means it is in the top 20% of more than 4,000 stocks that we rank based on trends in earnings estimate revisions and EPS surprises. This is a more conclusive indication of the stock's potential turnaround in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .

Phinia (PHIN - Free Report) has been beaten down lately with too much selling pressure. While the stock has lost 16.6% over the past four weeks, there is light at the end of the tunnel as it is now in oversold territory and Wall Street analysts expect the company to report better earnings than they predicted earlier.

We use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is oversold. This is a momentum oscillator that measures the speed and change of price movements.

RSI oscillates between zero and 100. Usually, a stock is considered oversold when its RSI reading falls below 30.

Technically, every stock oscillates between being overbought and oversold irrespective of the quality of their fundamentals. And the beauty of RSI is that it helps you quickly and easily check if a stock's price is reaching a point of reversal.

So, by this measure, if a stock has gotten too far below its fair value just because of unwarranted selling pressure, investors may start looking for entry opportunities in the stock for benefiting from the inevitable rebound.

However, like every investing tool, RSI has its limitations, and should not be used alone for making an investment decision.

Why PHIN Could Bounce Back Before LongThe RSI reading of 29.75 for PHIN is an indication that the heavy selling could be in the process of exhausting itself, so the stock could bounce back in a quest for reaching the old equilibrium of supply and demand.

This technical indicator is not the only factor that calls for a potential rebound for the stock. There is a fundamental indicator as well. A strong agreement among sell-side analysts covering PHIN in raising earnings estimates for the current year has led to an increase in the consensus EPS estimate by 0.2% over the last 30 days. And an upward trend in earnings estimate revisions usually translates into price appreciation in the near term.

Moreover, PHIN currently has a Zacks Rank #2 (Buy), which means it is in the top 20% of more than 4,000 stocks that we rank based on trends in earnings estimate revisions and EPS surprises. This is a more conclusive indication of the stock's potential turnaround in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .

NXP Semiconductors (NXPI - Free Report) has been on a downward spiral lately with significant selling pressure. After declining 20% over the past four weeks, the stock looks well positioned for a trend reversal as it is now in oversold territory and there is strong agreement among Wall Street analysts that the company will report better earnings than they predicted earlier.

We use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is oversold. This is a momentum oscillator that measures the speed and change of price movements.

RSI oscillates between zero and 100. Usually, a stock is considered oversold when its RSI reading falls below 30.

Technically, every stock oscillates between being overbought and oversold irrespective of the quality of their fundamentals. And the beauty of RSI is that it helps you quickly and easily check if a stock's price is reaching a point of reversal.

So, by this measure, if a stock has gotten too far below its fair value just because of unwarranted selling pressure, investors may start looking for entry opportunities in the stock for benefiting from the inevitable rebound.

However, like every investing tool, RSI has its limitations, and should not be used alone for making an investment decision.

Here's Why NXPI Could Experience a TurnaroundThe heavy selling of NXPI shares appears to be in the process of exhausting itself, as indicated by its RSI reading of 29.36. So, the trend for the stock could reverse soon for reaching the old equilibrium of supply and demand.

The RSI value is not the only factor that indicates a potential turnaround for the stock in the near term. On the fundamental side, there has been strong agreement among the sell-side analysts covering the stock in raising earnings estimates for the current year. Over the last 30 days, the consensus EPS estimate for NXPI has increased 0.6%. And an upward trend in earnings estimate revisions usually translates into price appreciation in the near term.

Moreover, NXPI currently has a Zacks Rank #2 (Buy), which means it is in the top 20% of more than 4,000 stocks that we rank based on trends in earnings estimate revisions and EPS surprises. This is a more conclusive indication of the stock's potential turnaround in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .

Key Takeaways TTEC delivers customer experience solutions through Digital consulting and Engage service segments.DAVE offers budgeting tools, ExtraCash overdraft advances and Dave Checking accounts.RAMP provides data collaboration, activation, measurement and analytics tools for marketers and enterprises. The technology services industry is mature, with demand for services in good shape. As a result, the industry flourished in 2025. The global shift toward digitization creates opportunities in various markets, including 5G, blockchain and artificial intelligence (AI). 

Companies are adopting generative AI, machine language (ML), blockchain and data science faster to gain a competitive advantage. Elevated demand for enterprise software, which is ramping up productivity and improving the decision-making process, is a key catalyst. 

However, this space has lost momentum in 2026 due to several macro-economic concerns and geopolitical conflicts. Despite these headwinds, we have narrowed our search to three small-sized technology services stocks with a favorable Zacks Rank that have provided double-digit returns year to date.

These companies are: TTEC Holdings Inc. (TTEC - Free Report) , Dave Inc. (DAVE - Free Report) and LiveRamp Holdings Inc. (RAMP - Free Report) . Each of our picks currently carries either a Zacks Rank #1 (Strong Buy) or 2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

The chart below shows the price performance of our three picks year to date.

Image Source: Zacks Investment Research

TTEC Holdings Inc.Zacks Rank #2 TTEC Holdings is a customer experience technology and services company. TTEC focuses on the design, implementation and delivery of customer experience. TTEC operates through the TTEC Digital and TTEC Engage segments. 

TTEC delivers outcome-based customer engagement solutions through TTEC Digital, a digital consultancy service that designs and builds human-centric, tech-enabled, insight-driven customer experience solutions for clients. TTEC Engage is a delivery center that operates customer acquisition, care, growth and digital trust and safety services.

TTEC Holdings has an expected revenue and earnings growth rate of -5% and 9.1%, respectively, for the current year. The Zacks Consensus Estimate for the current year’s earnings has improved 5.3% over the last 30 days. 

Dave Inc.Zacks Rank #1 Dave provides banking apps to build products in the financial playing field in the United States. DAVE offers Budget, a personal financial management tool that helps members anticipate upcoming transactions and receive notifications by utilizing historical bank account data to identify recurring charges.

DAVE also provides ExtraCash, a form of a discretionary overdraft to bridge liquidity gaps between paychecks, Side Hustle, a job application portal to find supplemental or temporary work and Dave Checking, a digital demand deposit account.

DAVE has an expected revenue and earnings growth rate of 25.4% and 9.9%, respectively, for the current year. The Zacks Consensus Estimate for the current year’s earnings has improved 3% over the last seven days. 

LiveRamp Holdings Inc.Zacks Rank #2 LiveRamp Holdings operates as a marketing technology company in the United States, Europe, the Asia-Pacific, and internationally. RAMP provides data foundation, digital transformation, consumer engagement, and online marketing and analysis services.

RAMP’s platform supports various people-based marketing solutions, including data collaboration, activation, measurement and analytics, identity, and data marketplace. RAMP sells its solutions to enterprise marketers, agencies, marketing technology providers, publishers, and data providers in various industry verticals

LiveRamp Holdings has an expected revenue and earnings growth rate of 8.6% and 31.8%, respectively, for next year (ending March 2027). The Zacks Consensus Estimate for the next year’s earnings has improved 0.4% over the last 30 days. 

LOS ANGELES, March 12, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Ramaco Resources, Inc. (“Ramaco” or “the Company”) (NASDAQ: METC) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company’s securities between July 31, 2025 and October 23, 2025, inclusive (the “Class Period”), are encouraged to contact the firm before March 31, 2026.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected].

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. Ramaco failed to commence meaningful mining operations at the Brook Mine after groundbreaking. The Company did not undertake active work at the Brook Mine during the Class Period, and overstated the progress it at made at the mine. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about Ramaco, investors suffered damages.

Join the case to recover your losses

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.        

CONTACT:

The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
[email protected]

SOURCE:

The Schall Law Firm

23.26K Followers

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

HILLERØD, Denmark--(BUSINESS WIRE)--FUJIFILM Biotechnologies, a world-leading contract development and manufacturing organization (CDMO) for biologics, vaccines, and advanced therapies, today announced the appointment of Christiane Bardroff as Chief Business Officer (CBO), effective June 1, 2026. Bardroff will lead commercial and sales, business insights and intelligence, strategic partnerships and global marketing, reporting directly to President and CEO Lars Petersen. Bardroff brings more tha.

New Appointments Bring Deep Expertise in Immunology and Infectious Disease to Advance IND Submission and Intellectual Property Strategy

Jericho, New York, March 12, 2026 (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals Inc. (Nasdaq: CURX) (“Curanex” or the “Company”), a development-stage pharmaceutical company focused on the discovery and development of botanical drugs for the treatment of inflammatory diseases, today announced the appointment of two highly respected and accomplished life sciences research experts to the Company’s Scientific Advisory Board. Dr. Taku Kambayashi and Dr. Selvakumar Subbian bring world-class expertise in immunology and infectious disease, directly aligned with the Company’s therapeutic focus and clinical development roadmap.

The Company intends to disclose one, final accepted member of its initial Scientific Advisory Board once that Advisor’s current employer, a well-known US academic institution, approves the draft press release.

These Advisors will provide scientific guidance across research and development, preclinical study design, IND preparation, clinical trials and intellectual property strategy. The biographical summary for these two Advisors is as follows:

Taku Kambayashi, MD, Ph.D.

Taku Kambayashi is a Professor of Pathology and Laboratory Medicine at the University of Pennsylvania's Perelman School of Medicine. A physician-scientist with dual clinical and research expertise, Dr. Kambayashi is board-certified in Clinical Pathology and Transfusion Medicine and serves as Chair of the Immunology Graduate Group at Penn.

Dr. Kambayashi’s laboratory investigates targetable signal transduction pathways in immune cells, with the goal of translating fundamental discoveries into therapies for autoimmune and inflammatory diseases. Key research programs include the role of TSLP-stimulated T cells in sebum secretion and adipose tissue loss (a finding with implications for obesity-related disorders), regulatory T cell homeostasis and its therapeutic manipulation in diseases such as multiple sclerosis, graft-versus-host disease, diabetes, and diacylglycerol kinase (DGK) as a novel checkpoint target for reactivating exhausted T cells in cancer and chronic infection.

Dr. Kambayashi earned his B.S. in Biomedical Engineering from Johns Hopkins University and his M.D. and Ph.D. from Emory University. He completed his residency and fellowship training at the Hospital of the University of Pennsylvania. His work has been recognized with numerous awards, including the National Blood Foundation Scholar Award, the Junior Faculty Scholar Award from the American Society of Hematology, the STAT Summit Breakthrough Science Award (2022), and the Lady Barbara Colyton Award for Autoimmune Research. He is a member of the American Society of Clinical Investigation and the Henry Kunkel Society.

Selvakumar Subbian, Ph.D.

Selvakumar Subbian is a Professor in the Department of Medicine and Principal Investigator at the Public Health Research Institute (PHRI), New Jersey Medical School, Rutgers University, Newark, NJ. With more than 25 years of expertise in microbial pathogenesis and host-pathogen interactions, his research focuses on pulmonary infectious diseases — particularly tuberculosis and COVID-19 — integrating animal models, systems biology, and translational approaches to investigate host immune responses, transcriptional regulation in bacterial pathogens, genome-wide transcriptional analysis, biomarker discovery, and host-directed therapeutic strategies.

Dr. Subbian's laboratory has pioneered the use of rabbit models of pulmonary tuberculosis to study disease states that closely mirror human TB, including active cavitary disease, spontaneous latency, and tuberculous meningitis. His team has made significant contributions to host-directed therapy (HDT) for TB, demonstrating that phosphodiesterase-4 (PDE4) inhibition can improve antibiotic efficacy and reduce lung pathology.

Dr. Subbian earned his B.Sc. in Biochemistry from Bharathiar University (India), his M.Sc. in Biomedical Genetics from the University of Madras, and his Ph.D. in Basic Medical Sciences from the Tuberculosis Research Center of the Indian Council of Medical Research, affiliated with The Tamil Nadu Dr. MGR Medical University. He completed postdoctoral training at the University of Nebraska–Lincoln, Texas A&M Health Science Center, and PHRI at New Jersey Medical School. He has authored more than 110 peer-reviewed publications and seven book chapters, serves as a reviewer for more than 75 scientific journals and multiple international funding agencies including NIH/NIAID, and is an editorial board member for several international journals. His honors include the "Faculty of the Year" award from New Jersey Medical School (2021) and the Young Investigator Award from the Theobald Smith Society of the American Society for Microbiology (2017).

Jun Liu, the Chief Executive Officer of Curanex, commented “We are honored to welcome Dr. Kambayashi and Dr. Subbian to our Scientific Advisory Board. Their deep expertise in immune signaling, host–pathogen interactions, and translational medicine is directly relevant to Curanex’s mission and will be invaluable as we complete our FDA-required preclinical studies and prepare our IND submission and clinical trials, targeted in the fourth quarter of 2026. Their scientific rigor and breadth of experience will strengthen our research strategy and help position us for a successful path to regulatory approval.”

About Curanex Pharmaceuticals Inc

Curanex Pharmaceuticals Inc is a developmental-stage pharmaceutical company headquartered in Jericho, New York, dedicated to discovering and developing botanical drugs for inflammatory diseases. Its lead candidate, Phyto-N, is a botanical extract from a single plant with proven anti-inflammatory properties that acts via multiple targets and mechanisms. Phyto-N has a long history of human use, having treated thousands of patients with inflammatory diseases over 30 years in China, demonstrating favorable tolerability.

The Company has validated Phyto-N's effects in animal models of six inflammatory diseases: ulcerative colitis, atopic dermatitis, COVID-19, diabetes, nonalcoholic fatty liver disease, and gout. The Company's primary development focus is moderate to severe ulcerative colitis. Phyto-N is currently advancing through FDA-required preclinical studies in preparation for an Investigational New Drug (IND) submission, with Phase I clinical trials targeted to initiate in the fourth quarter of 2026, pending completion of required studies and regulatory clearance.

For more information, visit the Company’s website at www.curanexpharma.com.

Forward-Looking Statements

All statements other than statements of historical fact in this announcement are forward-looking statements. These forward-looking statements are made as of the date hereof and involve known and unknown risks and uncertainties and are based on current expectations and projections about future events and financial trends that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can identify these forward-looking statements by words or phrases such as “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to” or other similar expressions. The Company undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s registration statement and in its other filings with the SEC.

For more information, please contact:

Curanex Pharmaceuticals Inc

Attn: Liqin Xie, Chief Operating Officer

[email protected].

Toronto, Ontario – March 12th, 2026 – TheNewswire – Blue Horizon Global Capital Corp. (the “Company”) (CSE: BHCC) is pleased to report the financial results of its investment in Sensor Technologies Inc. (“STI”), for the year ended December 31, 2025, as compared to the year ended December 31, 2024. The Company holds a 25% equity interest. Further to its press release of August 7, 2024, the Company also announces that it has amended the terms of the secured revolving line of credit facility dated July 23, 2024 (the “2024 Credit Facility”) entered into between the Corporation and an arm’s length third party (the “Creditor”).

  The following financial information has been derived from STI’s financial statements for the year ended December 31, 2025.

Financial Highlights

Sales revenue of $889,712, compared to $517,817 in 2024, representing an increase of approximately 72%. 

Gross profit of $599,790, compared to $410,016 in 2024, representing an increase of approximately 46%. 

Income before royalty payable to parent company of $180,255, compared to $18,520 in 2024. 

Net income of $175,749, compared to $18,520 in 2024, representing an increase of approximately 849%. 

Revenue growth was primarily attributable to expanded commercial deployments and increased customer adoption of STI’s sensor technology platform. Gross margins remained strong despite increased cost of sales associated with higher production volumes.

Total operating expenses for 2025 were $419,535, compared to $391,496 in 2024. The increase was primarily driven by higher professional fees and insurance expenses. Research and development expenditures remained consistent year-over-year, reflecting continued investment in product development and innovation. Payroll and finance costs declined compared to the prior year.

After accounting for a royalty payable to the parent company in the amount of $4,506 (2024: nil), STI generated net income of $175,749 for fiscal 2025.

Management believes the significant improvement in financial performance reflects the successful commercialization of STI’s technology, disciplined cost management, and increased recurring revenue traction.

Amendment to Credit Facility

The 2024 Credit Facility could not have exceeded $200,000 at any given time, had a maturity date of August 1, 2024, and bore interest at a fixed annual rate of 14.96% and was secured against all of the assets of the Corporation.

The 2024 Credit Facility was amended as follows:

(i) the maximum amount permissible under the facility was increased from $200,000 to $400,000; 

(ii) maturity date extended to March 10, 2027. 

All other terms of the 2024 Credit Facility remain the same.

Clarification

The Corporation wishes to issue a clarification regarding its press release dated February 9, 2026. In that announcement, it was stated that the transaction with C2 Technology Innovations Ltd. (“C2”) was terminated due to a requirement by the CSE for an independent third-party valuation of C2 and its technologies. The actual reason for terminating the transaction was the absence of sufficient evidence to support the proposed valuation for the acquisition.

About Sensor Technologies Inc.

Sensor Technologies Inc. is a technology-focused company engaged in the development and commercialization of advanced sensor systems designed to enhance monitoring, data acquisition, and operational efficiency across industrial and environmental applications.

About Blue Horizon Global Capital Corp.

Blue Horizon is an investment company whose primary objective is to identify promising companies with excellent projects, innovative technologies or both, using management’s extensive experience in deal sourcing and capital combination to maximize returns for its shareholders.

Forward-Looking Information

This news release contains certain forward-looking information within the meaning of applicable Canadian securities legislation.

For further information, please contact:

Alex MacKay

CEO & CFO

Blue Horizon Global Capital Corp.

Email: [email protected]

The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this news release.

LOS ANGELES, March 12, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Beyond Meat, Inc. (“Beyond Meat” or “the Company”) (NASDAQ: BYND) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company’s securities between February 27, 2025 and November 11, 2025, inclusive (the “Class Period”), are encouraged to contact the firm before March 24, 2026.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected].

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. Beyond Meat carried a higher book value for long-lived assets than their fair value. The Company was likely to be required to record a non-cash impairment charge due to this issue. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about Beyond Meat, investors suffered damages.

Join the case to recover your losses.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.        

CONTACT:

The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
[email protected]

SOURCE:

The Schall Law Firm

374Water Inc (NASDAQ:SCWO, FRA:8LL) said on Thursday it has received a purchase order from Garney Construction tied to a municipal project in Olathe, Kansas, marking a commercial step in deploying its technology to destroy PFAS-contaminated biosolids.

The order triggers a $2.3 million invoice and payment to the North Carolina-based waste treatment technology company and advances the next phase of the project, which involves construction and integration work led by Garney Construction.

Garney, a contractor focused on water and wastewater treatment infrastructure, was selected to lead construction activities for the project on behalf of the City of Olathe.

The project will deploy 374Water’s AirSCWO technology, which the company says can safely and permanently destroy per- and polyfluoroalkyl substances (PFAS) contained in municipal biosolids.

“Receiving this Purchase Order from Garney Construction is a significant step forward — it signals that the Olathe project is fully in motion and that our technology is being put to work solving one of the most critical waste management challenges,” Sunny Viswanathan, vice president of solutions at 374Water, said in a statement.

374Water said the Olathe deployment reflects rising demand from municipalities seeking alternatives to conventional disposal methods such as land application, incineration, and landfill disposal for PFAS-contaminated biosolids.

The company said projects such as the Olathe initiative could help accelerate adoption of its AirSCWO technology across municipal and industrial waste treatment markets.

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Duolingo To Contact Him Directly To Discuss Their Options

If you suffered significant losses in Duolingo stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

[You may also click here for additional information]

, /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Duolingo, Inc. ("Duolingo" or the "Company") (NASDAQ: DUOL).

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.

James (Josh) Wilson, Faruqi & Faruqi Senior Partner (PRNewsfoto/Faruqi & Faruqi, LLP) Duolingo Inc. shares tumbled as much as 22% on February 27th after the company said its drive to gain subscribers would mean slower earnings growth and narrower profit margins in the short term. The language-learning app company said it would step up investment in artificial intelligence and sacrifice some degree of monetization in order to accelerate user growth and engagement, with the goal of doubling the current number of daily active users to 100 million in 2028. "The short-term implication is that this year will see slower bookings growth and lower profitability," Chief Executive Officer Luis von Ahn said in a letter to shareholders. Daily active users grew the slowest in four years, rising 30% in the quarter from a year ago. The company expects first-quarter adjusted Ebitda of $73.6 million, trailing analyst estimates of $84 million.

To learn more about the Duolingo investigation, go to www.faruqilaw.com/DUOL or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Follow us for updates on LinkedIn, on X, or on Facebook.

Attorney Advertising.  The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com).  Prior results do not guarantee or predict a similar outcome with respect to any future matter.  We welcome the opportunity to discuss your particular case.  All communications will be treated in a confidential manner.

SOURCE Faruqi & Faruqi, LLP

Also from this source

HomeStock IdeasLong IdeasTech 

SummaryNebius Group N.V. secures a $2B Nvidia investment, gaining early access to cutting-edge Rubin architecture, Vera CPUs, and BlueField storage for hyperscale AI cloud expansion.NBIS targets over 5 GW of AI compute capacity by 2030, aiming to rival major hyperscale providers and deliver superior performance per rack and lower inference costs.Valuation appears stretched at $112/share (EV/sales 7.65x), with the market pricing in aggressive growth and strategic synergies from the Nvidia partnership and non-core assets.NBIS's 28% stake in ClickHouse and Avride subsidiary provides balance sheet flexibility and strategic integration, supporting long-term AI infrastructure ambitions. Hugo Kurk/iStock via Getty Images

Thesis As you know, there's a new partnership now announced between Nvidia Corporation (NVDA) and Nebius Group N.V. (NBIS). As far as the expansion of hyperscale AI cloud infrastructure goes, this

1.06K Followers

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Scan QR code to install app

Important DisclaimersFXEmpire is owned and operated by Empire Media Network LTD., Company Registration Number 514641786, registered at 7 Jabotinsky Road, Ramat Gan 5252007, Israel. The content provided on this website includes general news and publications, our personal analysis and opinions, and materials provided by third parties. This content is intended for educational and research purposes only. It does not constitute, and should not be interpreted as, a recommendation or advice to take any action, including making any investment or purchasing any product. Before making any financial decision, you should conduct your own due diligence, exercise your own discretion, and consult with competent advisors. The content on this website is not personally directed to you, and we do not take into account your individual financial situation or needs. The information contained on this website is not necessarily provided in real time, nor is it guaranteed to be accurate. Prices displayed may be provided by market makers and not by exchanges. Any trading or other financial decision you make is entirely your own responsibility, and you must not rely solely on any information provided through the website. FXEmpire does not provide any warranty regarding the accuracy, completeness, or reliability of any information contained on the website and shall bear no responsibility for any trading losses you may incur as a result of using such information. The website may include advertisements and other promotional content. FXEmpire may receive compensation from third parties in connection with such content. FXEmpire does not endorse, recommend, or assume responsibility for the use of any third-party services or websites. Empire Media Network LTD., its employees, officers, subsidiaries, and affiliates shall not be liable for any loss or damage resulting from your use of the website or reliance on the information provided herein.Risk DisclaimersThis website contains information about cryptocurrencies, contracts for difference (CFDs), and other financial instruments, as well as about brokers, exchanges, and other entities trading in such instruments. Both cryptocurrencies and CFDs are complex instruments and involve a high risk of losing money. You should carefully consider whether you understand how these instruments work and whether you can afford to take the high risk of losing your money. FX Empire encourages you to conduct your own research before making any investment decision and to avoid investing in any financial instrument unless you fully understand how it works and the risks involved.

Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Hub Group To Contact Him Directly To Discuss Their Options

If you suffered significant losses in Hub Group stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

[You may also click here for additional information]

, /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Hub Group, Inc. ("Hub Group" or the "Company") (NASDAQ: HUBG).

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.

James (Josh) Wilson, Faruqi & Faruqi Senior Partner (PRNewsfoto/Faruqi & Faruqi, LLP) On February 6, 2026, Hub Group shares fell sharply, after the logistics company disclosed a $77 million accounting error related to purchased transportation costs and accounts payable, prompting a restatement of prior financial results. The company said the error did not impact cash flow, but investors reacted negatively to the disclosure, sending the stock down as much as roughly 25% intraday. The announcement coincided with the release of preliminary fourth-quarter and full-year 2025 results and a delay in filing updated financial statements.

To learn more about the Hub Group investigation, go to www.faruqilaw.com/HUBG or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Follow us for updates on LinkedIn, on X, or on Facebook.

Attorney Advertising.  The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com).  Prior results do not guarantee or predict a similar outcome with respect to any future matter.  We welcome the opportunity to discuss your particular case.  All communications will be treated in a confidential manner.

SOURCE Faruqi & Faruqi, LLP

Also from this source

TSS, Inc. (TSSI) is a microcap AI infrastructure firm with rapid scale-up, but remains heavily reliant on low-margin procurement revenue. Gross margin stagnates at 11.1%, with high-margin segments producing ~4x more profit per dollar but comprising only 16% of revenue. Balance sheet strength has improved significantly, with unrestricted cash at $70.7M and net working capital at $34.3M as of September 2025.

March 12, 2026 08:30 ET  | Source: FibroBiologics, Inc.

HOUSTON, March 12, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using proprietary fibroblast spheroid technology, today announced the expansion of its wound care platform into the treatment of patients with acute and chronic burn injuries.

Building on its investigational fibroblast spheroid-based programs in chronic wound healing, FibroBiologics is applying the same core technology to address the significant unmet medical needs in burn care, where current standards of care often result in prolonged healing, multiple procedures, and substantial scarring.

In preclinical burn models, treatment with proprietary fibroblast spheroids (CYWC628) was associated with nearly a four-fold increase in tissue-level IL-10, a cytokine known to support tissue repair and wound healing in skin.​

Additionally, CYWC628 drove a significant reduction in IL-1B, a key driver of inflammation in burn wounds, further supporting the potential of the platform to promote better, faster healing in patients with severe burns.​

These findings suggest that CYWC628 may both accelerate wound closure and improve the quality of healed tissue by simultaneously promoting regeneration and dialing down harmful inflammation.​

“These new burn data reinforce our conviction that fibroblast spheroids can reshape how serious wounds are treated,” said Pete O’Heeron, Founder and Chief Executive Officer of FibroBiologics. “By combining strong signals of tissue repair with meaningful reductions in inflammatory markers, CYWC628 positions us to address a large, underserved market in burn care and create significant benefit for patients. We believe that a targeted, cell-based approach has the potential to improve healing outcomes, reduce complications, and ultimately change the standard of care for burn patients worldwide.”​

“From a scientific standpoint, seeing nearly a four-fold increase in IL-10 alongside a significant reduction in IL-1B in burn tissue is highly encouraging,” noted Hamid Khoja, Ph.D., Chief Scientific Officer of FibroBiologics. “These tissue-level biomarker changes align with the type of regenerative, pro-healing environment we are aiming to create in complex wounds and give us confidence as we advance CYWC628 toward clinical development in burn patients.”

Burns remain a major global health concern with significant unmet needs, with the worldwide burn care market estimated to be $2.55B worldwide and growing to $3.35B by the year 2030 (Markets & Makers 2025), driven by rising incidence and continued demand for advanced wound care solutions. FibroBiologics intends to integrate its burn program within its broader wound care strategy as it evaluates next steps toward clinical development.

About FibroBiologics

Based in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and seeking potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 270+ US and internationally issued patents/patents pending across various clinical pathways, including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy and tissue regeneration. 

For more information, please visit FibroBiologics' website, email FibroBiologics at [email protected] or follow FibroBiologics on LinkedIn, YouTube, Facebook or X.

Cautionary Statement Regarding Forward-Looking Statements
This communication contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements include information concerning plans for FibroBiologics’ research and development programs, the robustness, progress, and momentum of FibroBiologics’ research and development program, the potential indications for FibroBiologics’ programs, the potential of product candidates as scalable platform technologies, estimates of market size, and the potential clinical benefits of fibroblasts and fibroblast-derived materials, including changing the standard of care for burn patients worldwide. These forward-looking statements are based on FibroBiologics' management's current expectations, estimates, projections and beliefs, as well as a number of assumptions concerning future events. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside FibroBiologics' management's control, that could cause actual results to differ materially from the results discussed in the forward-looking statements, including those set forth under the caption "Risk Factors" and elsewhere in FibroBiologics' annual, quarterly and current reports (i.e., Form 10-K, Form 10-Q and Form 8-K) as filed or furnished with the SEC and any subsequent public filings. Copies are available on the SEC's website, www.sec.gov. These risks, uncertainties, assumptions and other important factors include, but are not limited to: (a) risks related to FibroBiologics' liquidity and its ability to maintain capital resources sufficient to conduct its business; (b) expectations regarding the initiation, progress and expected results of FibroBiologics’ R&D efforts and preclinical studies; and (c) the unpredictable relationship between R&D and preclinical results and clinical study results. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and FibroBiologics assumes no obligation and, except as required by law, does not intend to update, or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. FibroBiologics gives no assurance that it will achieve its expectations.

General Inquiries:
[email protected]

Investor Relations:
Nic Johnson
Russo Partners
(212) 845-4242
[email protected]

Media Contact:
Liz Phillips
Russo Partners
(347) 956-7697
[email protected]

NEW YORK and MIAMI, March 12, 2026 (GLOBE NEWSWIRE) -- House of Doge, the official corporate arm of the Dogecoin Foundation, along with merger partner Brag House Holdings (NASDAQ:TBH) today shared commentary from CEO Marco Margiotta on the accelerating convergence of traditional finance and digital payments and how the company is positioning Dogecoin’s massive community to participate in this shift.

Crypto-linked debit card spending has reached an $18 billion annualized run rate1, growing more than 15× since 2023, signaling a major shift toward real-world crypto usage. This has been supported by global payment networks and widespread merchant acceptance. Industry research suggests crypto card spending now rivals peer-to-peer stablecoin transfers in scale, underscoring that digital assets are increasingly being used for everyday consumer purchases rather than remaining confined to trading and wallet-to-wallet activity.

“Cards are the bridge between digital currency and everyday life,” said Marco Margiotta, CEO of House of Doge. “When digital assets can be spent anywhere traditional cards are accepted, adoption accelerates dramatically. This is the moment where crypto moves from speculation to real-world utility.”

Momentum in the category is also being reinforced by major global payment networks. Visa said it supports more than 130 stablecoin-linked card issuing programs across more than 40 countries2, while Mastercard says its crypto card programs enable spending across more than 150 million acceptance locations3 and has launched a new Crypto Partner Program with more than 85 industry leaders4. Together, these developments suggest crypto-linked cards are evolving from a niche product into a more established part of the global payments landscape.

Bridging Dogecoin with card based payments would activate one of the world’s most popular digital currencies everywhere, instantly. “Rather than rebuilding the financial system from scratch, we are working towards integrating Dogecoin into the rails that already connect millions of merchants and billions of consumers worldwide. Partnerships allow us to lower development costs, reduce regulatory friction, and dramatically accelerate time to market.”

“The fastest path to adoption is meeting users where they already are,” Margiotta added. “That means wallets, cards, mobile payments, and global payment networks. Consumers won’t think in terms of crypto or fiat—they’ll simply pay. Our goal is to make Dogecoin part of that seamless experience.”

As digital asset spending continues to grow, House of Doge sees a significant opportunity to help bridge traditional finance and the next generation of internet-native money.

About House of Doge
House of Doge is the official corporate arm of the Dogecoin Foundation, committed to advancing Dogecoin ($DOGE) as a widely accepted and decentralized global currency. By investing in the infrastructure needed to bring Dogecoin into everyday commerce, House of Doge is building secure, scalable, and efficient systems for real-world use. From payments and financial products to real-world asset tokenization and cultural partnerships, House of Doge is leading the next era of crypto utility, where Dogecoin goes beyond the meme and fulfills its mission of Doing Only Good Everyday on a global scale.

About Brag House
Brag House is a leading media technology gaming platform dedicated to transforming casual college gaming into a vibrant, community-driven experience. By seamlessly merging gaming, social interaction, and cutting-edge technology, the Company provides an inclusive and engaging environment for casual gamers while enabling brands to authentically connect with the influential Gen Z demographic. The platform offers live-streaming capabilities, gamification features, and custom tournament services, fostering meaningful engagement between users and brands. For more information, please visit www.braghouse.com.

Media Contacts

House of Doge
Angela Gorman
Communications Director
Email: [email protected]
Tel: (917) 348-0083

Brag House Holdings
Fatema Bhabrawala
Director of Media Relations
[email protected]

Investor Relations Contact
Brag House Holdings
Adele Carey
VP, Investor Relations
[email protected]

____________________________

1https://www.coindesk.com/business/2026/01/16/crypto-card-spending-hits-usd18-billion-annualized-as-stablecoin-use-shifts-to-everyday-payments
2https://s1.q4cdn.com/050606653/files/doc_financials/2025/q4/CORRECTED-TRANSCRIPT_-Visa-Inc-V-US-Q4-2025-Earnings-Call-28-October-2025-5_00-PM-ET.pdf?utm_source=chatgpt.com
3https://www.mastercard.com/us/en/business/payments/consumer-payments/next-gen-payments/digital-asset-solutions/crypto-card-program.html
4 https://www.mastercard.com/us/en/news-and-trends/stories/2026/mastercard-crypto-partner-program.html

March 12, 2025 – TheNewswire - Montreal, Quebec, Canada - BGFBeauce Gold Fields (Champs d’Or en Beauce) (TSX Venture: BGF), referred to as “BGF” or the “Company,” is pleased to report analytical results from apatite rock samples collected on its CH-98 Phosphate Property in the Lac-Saint-Jean region of Québec, along with metallurgical test results conducted by COREM on apatite-bearing material collected from the property.  The results follow the Company’s November 17, 2025 press release, which reported the presence of apatite-rich anorthosite and confirmed the historic CH-98-61 phosphate showing.Patrick Levasseur, President and CEO of Beauce Gold Fields, commented: “The assays confirm significant phosphate values at the CH-98-61 showing, while COREM test work demonstrates that apatite from the property can be upgraded to a high-grade phosphate concentrate using conventional flotation methods. These results support the CH-98 property as a promising component of our Québec Phosphate strategy. Our goal is to advance near-surface targets and position Beauce Gold Fields to contribute a secure North American phosphate supply chain.”

Click Image To View Full Size

  Image: Apatite-bearing anorthosite rock sample CH-98-61

Apatite Rock Assay Results

During the 2025 field visit to the CH-98 property, apatite rock samples collected from five locations including samples taken directly from the CH-98-61 outcrop showing, were submitted for analysis to ALS Canada Ltd. in Val-d’Or, Québec, for whole-rock geochemical analysis using XRF methods.

Results include:

Sample

Field ID

P₂O₅ (%)

D589656

2025-0112

1.95

D589657

2025-0113

3.01

D589659

2025-0115

4.31

D589660

CH-98-C

0.28

D589661

CH-98-61

8.07

The 8.07% P₂O₅ result from sample CH-98-61 confirms the high-grade phosphate values previously reported from historical government sampling, which recorded 8.59% P₂O₅ from the same outcrop showing.  The sampled rocks consist primarily of apatite-bearing anorthosite, a known host lithology for phosphate deposits within the Lac-Saint-Jean anorthositic suite.

COREM Metallurgical Test Results

A 20 kg rock sample of apatite-bearing material from the CH-98-61 outcrop was submitted to COREM (Québec City) to evaluate the potential to produce an apatite concentrate by flotation.

COREM flotation tests demonstrated that the material responded well to conventional mineral processing methods.

  Key results include:

Production of high-grade apatite concentrates exceeding 35% P₂O₅ 

Best flotation test produced 38.9% P₂O₅ concentrate 

93.4% P₂O₅ recovery 

Low impurity levels with MER (minor element ratio) of 0.05 

These results indicate that apatite contained in the CH-98 material can be effectively upgraded using conventional flotation techniques.

Additional characterization of the concentrate showed:

0.19% total rare earth oxides (TREO) 

Low thorium (<5 ppm) and uranium (1.3 ppm) 

The metallurgical testing was conducted on material containing approximately 5.6% P₂O₅ in the feed sample prior to concentration.

The apatite concentrate grades obtained in the COREM flotation tests are comparable to concentrate grades reported by advanced phosphate projects in the Lac-Saint-Jean anorthosite district, where concentrates commonly range from approximately 35% to 40% P₂O₅ following flotation beneficiation. The test work completed on material from the CH-98 property produced concentrates grading up to 38.9% P₂O₅ with 93.4% recovery, demonstrating that apatite mineralization from the property can be upgraded using conventional flotation techniques consistent with those used by other phosphate developments in the region.

Next Steps

The Company plans to advance exploration on the CH-98 property through:

Detailed mapping and prospecting 

Channel sampling of apatite-bearing outcrops 

Geophysical surveys to trace favourable lithologies and structures 

Evaluation of additional metallurgical samples 

These activities aim to determine the lateral continuity and scale of apatite mineralization on the property.

Quality Assurance / Quality Control

Rock samples collected during the 2025 field program were delivered to ALS Canada Ltd. in Val-d’Or, Québec, an ISO-certified analytical laboratory. Samples were crushed, split, and pulverized prior to analysis. Whole-rock geochemistry, including P₂O₅, was determined by X-ray fluorescence (XRF) analysis following lithium borate fusion preparation.

  The analytical program included internal laboratory quality control procedures including standards, blanks, and duplicates. ALS Canada operates under internationally recognized quality assurance protocols to ensure analytical accuracy and precision. The Company’s qualified person has reviewed the laboratory analytical procedures and considers them appropriate for the style of mineralization being tested.

Metallurgical test work on material from the CH-98 property (Passes-Dangereuses area) was conducted by COREM, Québec City, an independent mineral processing research center. Approximately 13.8 kg of representative rock material was prepared by crushing and homogenization before being split into test charges for flotation experiments.

The sample was characterized by XRF analysis prior to testing and contained approximately 5.6% P₂O₅ in the head sample. Flotation tests were carried out in laboratory Denver flotation cells using a reagent scheme including fatty acid collectors and depressants to separate apatite from silicate and iron-bearing minerals.

Multiple flotation tests were conducted at varying grind sizes to evaluate concentrate grade and recovery. The results reported represent the outcomes of controlled laboratory test conditions designed to evaluate the potential to produce an apatite concentrate and do not represent process optimization or economic feasibility studies. The Company’s Qualified Person has reviewed the COREM metallurgical procedures and considers the test work appropriate for preliminary evaluation of phosphate mineralization from the CH-98 property.  Source COREM T3913 Final Report

The technical information contained in this news release has been reviewed and approved by Christian Tremblay, M.Sc., P.Geo., an independent Qualified Person as defined by National Instrument 43-101.

Advancing Québec Phosphate

The CH-98 property forms part of Beauce Gold Fields’ broader Québec Phosphate initiative, which targets phosphate occurrences within the Lac-Saint-Jean anorthosite complex, one of North America’s most important phosphate-titanium districts.

Phosphate is essential for fertilizers and is a key component of LFP (lithium iron phosphate) battery cathodes. The Company’s strategy is to advance near-surface targets with potential to contribute to North America’s critical minerals supply chain.  Phosphate was recently added to Canada’s and Québec’s critical minerals lists

About Beauce Gold Fields

Beauce Gold Fields is focused on exploring and developing the largest placer gold district in eastern North America. The Company’s objective is to trace old placer gold workings back to a bedrock source to uncover economic lode gold deposits.  The Company’s flagship property is the Saint-Simon-les-Mines gold project, site of Canada’s first gold rush that pre-dates the Yukon Klondike.  The Beauce region hosted some of the largest historical placer gold mines in Eastern North America that were active from the 1860s to the 1960s. These operations produced some of the largest gold nuggets in Canadian mining history (50oz+). (Source Sedar: 43-101 Report - Beauce July 4th 2018, Author B. Violette)

  Beauce Gold Fields is currently drilling recently discovered antiform systems that are believed to have contributed to the development of extensive auriferous placer deposits in Beauce.  The Company’s geological model suggests that placer gold within the Beauce Gold paleochannel, including the renowned large nuggets from the 19th century, formed in stressed quartz pockets within layered domed axes of antiform structures, exemplified by Saddle Reef formations. Notable global Saddle Reef formations include the Bendigo gold fields in Australia (over 60 million ounces) and the high-grade Dufferin gold deposit in Nova Scotia.

  Beauce Gold Fields website www.beaucegold.com

  Disclaimers:

This press release contains certain forward-looking statements, including, without limitation, statements containing the words "may", "plan", "will", "estimate", "continue", "anticipate", "intend", "expect", "in the process" and other similar expressions which constitute "forward-looking information" within the meaning of applicable securities laws. Forward-looking statements reflect the Company's current expectation and assumptions, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties including, but not limited to, our expectations regarding mineral exploration. Such statements reflect the current views of the Company with respect to future events and are subject to certain risks and uncertainties and other risks detailed from time-to-time in the Company's on-going filings with the securities regulatory authorities, which filings can be found at www.sedarplus.ca. Actual results, events, and performance may differ materially. Readers are cautioned not to place undue reliance on these forward-looking statements. The Company undertakes no obligation to publicly update or revise any forward-looking statements either as a result of new information, future events or otherwise, except as required by applicable securities laws.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

For further information contact

Patrick Levasseur, President and CEO Tel: (514) 262-9239

www.beaucegold.com